Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

Last updated:
2026-07-25
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL GROUP, MULTICENTER 24 TO 52 WEEK VARIABLE LENGTH STUDY TO ASSESS THE EFFICACY AND SAFETY OF BUDESONIDE, GLYCOPYRRONIUM, AND FORMOTEROL FUMARATE METERED DOSE INHALER (MDI) RELATIVE TO BUDESONIDE AND FORMOTEROL FUMARATE MDI AND SYMBICORT® PRESSURIZED MDI IN ADULT AND ADOLESCENT PARTICIPANTS WITH INADEQUATELY CONTROLLED ASTHMA (KALOS)

Intervention/treatment:
BUDESONIDE-GLYCOPYRRONIUM-FORMOTEROL (PT010)/ BUDESONIDE-FORMOTEROL (PT009) / BUDESONIDE-FORMOTEROL (SYMBICORT PMDI)
Medical condition:
ASTHMA
Protocol code:
D5982C00007
Control number:
243980
Status:
Closed
Approved:
October 26, 2020
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT04609878
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
12 Years to 80 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Global Clinical Head
Organization
AstraZeneca
Phone:
1-877-240-9479
Sponsor
ASTRAZENECA CANADA INC

Locations

Alberta

Research Site
Edmonton, Alberta, T5A 4L8
Research Site
Sherwood Park, Alberta, T8H 2M7

British Columbia

Research Site
Kelowna, British Columbia, V1Y 4N7
Research Site
Vancouver, British Columbia, V5Z 1M9
Research Site
Vancouver, British Columbia, V6Z 1Y6

Manitoba

Research Site
Winnipeg, Manitoba, R2V 4W3
Research Site
Winnipeg, Manitoba, R3L 1Z5

Ontario

Research Site
Ajax, Ontario, L1S 2J5
Research Site
Burlington, Ontario, L7N 3V2
Research Site
Hamilton, Ontario, L8S 1G5
Research Site
London, Ontario, N6A 1V2
Research Site
Newmarket, Ontario, L3Y 5G8
Research Site
Niagara Falls, Ontario, L2H 1H5
Research Site
Toronto, Ontario, M5G 1E2
Research Site
Toronto, Ontario, M9V 4B4

Quebec

Research Site
Québec, Quebec, G1G 3Y8
Research Site
Québec, Quebec, G1V 4W2
Research Site
Québec, Quebec, G2J 0C4

Results

See the results from the trial NCT04609878. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?